A Phase 2 Study of Bortezomib Combined with Either Idarubicin/Cytarabine or Cytarabine/Etoposide in Children with Relapsed, Refractory or Secondary Acute Myeloid Leukemia: A Report from the Children's Oncology Group

BACKGROUND: This Phase 2 study tested the tolerability and efficacy of bortezomib combined with reinduction chemotherapy for pediatric patients with relapsed, refractory or secondary acute myeloid leukemia (AML). Correlative studies measured putative AML leukemia initiating cells (AML-LIC) before an...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Pediatr Blood Cancer
Asıl Yazarlar: Horton, Terzah M., Perentesis, John P., Gamis, Alan S., Alonzo, Todd A., Gerbing, Robert B., Ballard, Jennifer, Adlard, Kathleen, Howard, Dianna S., Smith, Franklin O., Jenkins, Gaye, Kelder, Angelé, Schuurhuis, Gerrit J., Moscow, Jeffrey A.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2014
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4247259/
https://ncbi.nlm.nih.gov/pubmed/24976003
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.25117
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller